Novotech, the Asia Pacific centered biotech specialist CRO, will attend JPM 2023 and experts from the US and Asia Pacific teams are available for meetings via BIO Partnering.

Novotech CEO Dr. John Moller is presenting at JPM on 11 January 2023. Dr. Moller has been invited to share Novotech’s growth and global expansion program.

Book a meeting with the Novotech team here

Novotech can share the benefits of Asia Pacific for expedited clinical trials where biotechs can access Novotech’s vast patient populations, local regulatory knowledge, extensive site and KOL network, and reputation for data quality.

Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.

The latest industry research publication by GlobalData and Novotech found almost 50% of new trials have sites in Asia Pacific.

According to the new publication titled State of the Global Biotech Landscape: Where the Opportunities Lie, demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.

The data shows almost 12,900 of the new trials had sites in Asia Pacific.

Download the report here

The report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. 

Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.

Frost & Sullivan said:

“Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement.

Novotech addresses the global drug development market’s unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation.

From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients.”
 

Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals.

The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway.

Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.

Download whitepaper here 

Novotech has also recently been benchmarked as a top 10 CRO among the world’s leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. 

關於Novotech健康控股

Novotech健康控股有限公司(“Novotech”)是亞太地區及美國領先的生物技術專家 CRO。 Novotech 是一家 CRO,擁有綜合實驗室和 I 期設施,提供藥物開發諮詢和臨床開發服務。它有助於在所有試驗階段和廣泛的治療領域成功進行大約 4,000 項臨床試驗。 Novotech具有明顯優勢,可以為在亞洲及美國進行臨床試驗的生物製藥客戶提供服務。詳細信息請訪問

https://novotech-cro.com/ct/contact

其他相關內容